Corticosteroid Toxicity, Drug Interactions, and Gout Pharmacology

Prednisone below 10 mg per day for less than two weeks carries low risk for opportunistic infections in otherwise immunocompetent patients. Prednisone at or above 20 mg per day for four weeks or longer substantially increases the risk of opportunistic infections, particularly PJP — formerly called Pneumocystis carinii pneumonia — which carries mortality rates of 30 to 50% in immunosuppressed patients. TMP-SMX is the preferred prophylactic agent, with a single-strength tablet daily (80 mg trimethoprim plus 400 mg sulfamethoxazole) providing nearly complete protection. TMP-SMX also provides prophylaxis against toxoplasmosis and nocardiosis. Current guidance recommends PJP prophylaxis for patients receiving prednisone at or above 20 mg per day for four weeks or longer in combination with other immunosuppressive agents. For patients intolerant of TMP-SMX, alternatives include dapsone, atovaquone, or inhaled pentamidine.

Latent TB can reactivate with immunosuppressive corticosteroid doses. All patients about to begin prolonged moderate-to-high dose corticosteroid therapy should be screened with an IGRA (such as QuantiFERON-TB Gold) or tuberculin skin test; IGRA is preferred in patients who have received BCG vaccination, as it does not produce false-positive results from that exposure. Active TB must be excluded clinically and radiologically. Patients with confirmed latent TB without active disease should receive isoniazid preventive therapy for nine months, ideally initiated at least four weeks before immunosuppression in non-urgent settings. In urgent clinical situations, corticosteroids and isoniazid can be started simultaneously.

HBV reactivation can cause fulminant hepatitis in immunosuppressed patients. All patients initiating corticosteroid therapy at or above prednisone 10 mg per day for four weeks or longer, or who will receive concurrent immunosuppressants, should be screened with hepatitis B surface antigen, total antibody to hepatitis B core antigen, and antibody to hepatitis B surface antigen. Patients who are hepatitis B surface antigen-positive (chronic HBV infection) require antiviral prophylaxis with a high-barrier nucleotide analogue (entecavir or tenofovir) continued for six to twelve months after immunosuppression ends. Patients with past infection (positive core antibody, negative surface antigen) have lower reactivation risk but warrant monitoring with HBV DNA levels during high-level immunosuppression.

Live attenuated vaccines — including measles-mumps-rubella, varicella-zoster, yellow fever, and intranasal influenza — are contraindicated in patients receiving prednisone at or above 20 mg per day for two weeks or longer, because corticosteroid-mediated immunosuppression can allow vaccine-strain replication and dissemination. Inactivated vaccines (injectable influenza, pneumococcal, recombinant zoster, tetanus-diphtheria-pertussis) are safe and should be given whenever feasible, ideally before immunosuppression begins. Steroid-sparing strategies — disease-modifying antirheumatic drugs, conventional immunosuppressants such as methotrexate and azathioprine, and targeted biologics — allow corticosteroid dose reduction and should be employed whenever the underlying condition permits, to minimize cumulative corticosteroid exposure and toxicity.

Three clinical entities can present with overlapping symptoms during corticosteroid tapering: adrenal insufficiency, corticosteroid withdrawal syndrome, and relapse of the underlying disease. Distinguishing them is clinically essential because their management differs completely.

Adrenal insufficiency is confirmed by a low morning serum cortisol (below 3 micrograms per deciliter) or subnormal cortisol response on ACTH stimulation testing. It may be accompanied by hyponatremia and hypoglycemia. Management requires slowing the taper and potentially temporarily increasing the dose; patients with persistent adrenal insufficiency may need stress dosing during physiological challenges.

Corticosteroid withdrawal syndrome is a distinct entity from adrenal insufficiency. It results from physiological dependence on supraphysiological GC concentrations: tissues that have adapted to chronically elevated GC receptor activation experience relative GC deficiency when drug levels decline, even when plasma cortisol is within the normal range. Symptoms include arthralgia, myalgia, fatigue, headache, and nausea — overlapping with adrenal insufficiency — but morning cortisol and ACTH stimulation testing are normal. There are no electrolyte abnormalities. Management requires patient education, reassurance, and a slower taper over a longer time course; dose escalation is not required and can perpetuate dependence.

Relapse of the underlying inflammatory disease is identified by recurrence of disease-specific symptoms alongside rising inflammatory markers. Management requires increased immunosuppressive therapy rather than simply adjusting the steroid taper pace.

Allopurinol is the most widely prescribed ULT and the first-line agent in most guidelines. It is a structural analogue of hypoxanthine that inhibits XO, the enzyme that catalyzes the final two steps of uric acid biosynthesis — conversion of hypoxanthine to xanthine and xanthine to uric acid. Allopurinol itself is rapidly metabolized by XO to oxypurinol, which is the primary pharmacologically active species. Oxypurinol has a long half-life and is renally cleared; dose adjustment is mandatory in chronic kidney disease to prevent oxypurinol accumulation, which is the principal pharmacokinetic cause of allopurinol hypersensitivity reactions.

The starting dose should be low — 50 to 100 mg per day — and titrated upward in increments every two to four weeks to achieve the serum urate target; doses well above 300 mg per day are frequently required and are safe with appropriate renal function monitoring. The allopurinol hypersensitivity syndrome is a rare but potentially fatal reaction characterized by fever, rash (ranging from maculopapular to Stevens-Johnson syndrome and toxic epidermal necrolysis), hepatitis, eosinophilia, and renal failure. Risk is substantially increased by starting at doses disproportionately high for the patient's renal function and by the HLA-B*5801 allele, which is more prevalent in East Asian populations. Initiating at a low dose and titrating slowly substantially reduces hypersensitivity risk regardless of genetic background.

Febuxostat is a non-purine selective XO inhibitor that is structurally unrelated to allopurinol and does not require dose adjustment for mild-to-moderate chronic kidney disease (eGFR at or above 30 mL per minute per 1.73 m²). This makes it useful in the subset of gout patients with renal insufficiency who cannot tolerate the required allopurinol dose reduction. Febuxostat is predominantly hepatically metabolized and excreted via bile, with limited renal dependence. A large clinical trial raised a cardiovascular safety concern by finding higher all-cause and cardiovascular mortality with febuxostat compared to allopurinol in patients with established cardiovascular disease. Current US guidance recommends allopurinol as first-line, with febuxostat reserved for patients who have failed or cannot tolerate allopurinol.

Uricosuric agents reduce serum urate by inhibiting the proximal tubular transporters (urate anion transporter 1 and glucose transporter 9) responsible for reabsorbing filtered urate, thereby increasing renal urate excretion. Probenecid is effective as monotherapy in gout patients with normal renal function and without a history of urolithiasis. Contraindications include eGFR below 30 mL per minute per 1.73 m² (insufficient urine flow for uricosuric effect) and urate overproduction with high urinary uric acid (increased urolithiasis risk). Low-dose aspirin at or below 325 mg per day blocks the uricosuric effect of probenecid by competing for tubular secretion transporters; this combination should be avoided when probenecid is used for gout management.

Pegloticase is a pegylated recombinant porcine uricase that converts uric acid to allantoin — the highly soluble metabolite that most mammals excrete — providing an enzymatic activity that humans lack. It is reserved for refractory tophaceous gout in patients who have failed or cannot tolerate conventional ULT, administered as an intravenous infusion every two weeks. The principal clinical challenge is immunogenicity: approximately 40 to 50% of patients develop antibodies against pegloticase that neutralize its hypouricemic effect and dramatically increase the risk of anaphylaxis and serious infusion reactions. Loss of the serum urate response — urate rising above 6 mg per deciliter during treatment — signals antibody formation and requires immediate drug discontinuation before the next infusion to prevent anaphylaxis. Co-administration of methotrexate (typically 15 mg per week) substantially reduces anti-drug antibody formation and is now endorsed in guidelines as a strategy to improve the proportion of patients who maintain a durable response.

Any ULT — whether XO inhibitor or uricosuric — reduces serum urate and mobilizes MSU crystals from tissue depots, triggering paradoxical gout flares in the first three to six months of therapy. This crystal shedding phenomenon is the primary reason patients discontinue ULT before reaching the target serum urate. Co-prescribing prophylactic low-dose colchicine (0.5 to 0.6 mg once or twice daily) for the first three to six months of ULT initiation substantially reduces flare frequency and improves ULT persistence. Low-dose NSAIDs or low-dose prednisone are alternatives when colchicine is contraindicated. Prophylaxis should continue for at least six months after achieving the serum urate target, and longer in patients with tophi.